AUS
NZ
UK
CA
USA
IND
Highlights:
- MIRA Pharmaceuticals develops Ketamir-2, a novel oral ketamine analog.
- Preclinical studies show Ketamir-2 surpasses FDA-approved treatments Gabapentin and Pregabalin for neuropathic pain.
- Ketamir-2 is non-habit forming and aims to avoid sedation and cognitive impairment.
MIRA Pharmaceuticals (NASDAQ:MIRA) is advancing the field of neuropathic pain treatment with the development of Ketamir-2, a novel oral ketamine analog. This sector is crucial as neuropathic pain, which stems from nerve damage, requires highly specialized treatments. Traditional treatments for this condition, such as Gabapentin and Pregabalin, have dominated the market, but the emergence of Ketamir-2 shows promising results in addressing gaps in these medications.
Ketamir-2 Performance in Preclinical Studies
Recent preclinical studies indicate that Ketamir-2 outperforms FDA-approved treatments for neuropathic pain, such as Gabapentin and Pregabalin. Ketamir-2 demonstrated significant improvements in providing relief from pain. By Day 22 of the studies, Ketamir-2 showed greater efficacy than both medications, particularly in higher doses, offering an alternative approach to pain management in the preclinical phase.
Benefits of Ketamir-2 Over Current Treatments
One of the notable aspects of Ketamir-2 is its non-habit-forming property, which sets it apart from many pain treatments that can lead to dependence. Furthermore, it offers the potential to avoid common side effects associated with traditional medications, such as sedation and cognitive impairment. These features make Ketamir-2 a notable candidate for further exploration in the pain management sector, where there is ongoing demand for safer alternatives.
Future Plans for Ketamir-2 Development
MIRA Pharmaceuticals is preparing to submit an Investigational New Drug (IND) application for Ketamir-2 by the end of the year. The next phases of development are already in motion, with Phase 1 clinical trials scheduled to commence in Q1 2025, followed by Phase 2 trials later that year. In addition to its application for neuropathic pain, the company is also exploring Ketamir-2’s use for treating PTSD, a condition often associated with severe trauma.
Exploring Funding and Development Opportunities
MIRA Pharmaceuticals is seeking government grants to expedite the development process for Ketamir-2. The goal is to accelerate research and bring this treatment to further clinical trials. This funding pursuit is critical for advancing the novel treatment through the necessary phases of testing and regulatory approval. Expanding Ketamir-2’s potential applications, particularly in areas like PTSD, will further enhance its profile in the field of medical treatments.
